Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Tocilizumab concentrations tied to clinical improvement in RA patients

11 Dec 2019

A personalized approach in the dosing of subcutaneous tocilizumab (TCZ) injections according to body weight appears to be effective in improving outcomes of clinical disease activity in patients with rheumatoid arthritis (RA), suggests a study.

“In the first 24 weeks of treatment with subcutaneous TCZ injections, TCZ concentrations were associated with clinical improvement, while body weight and body mass index (BMI) were inversely associated with TCZ concentrations,” the researchers said.

An analysis was conducted on datasets from the Israeli branch of the multinational TOZURA study, which evaluated a weekly subcutaneous TCZ treatment regimen in a real-life clinical setting, to determine whether serum TCZ trough concentrations administered as a fixed-dose subcutaneous injection for the treatment of RA correlated with disease activity responses.

The associations between TCZ levels and study outcomes were assessed using generalized estimating equations (GEE). Associations between patient characteristics and TCZ levels were evaluated using linear models and GEE.

TCZ concentrations significantly correlated with the change in the Clinical Disease Activity Index (CDAI) score. The multivariable binary GEE model revealed that each 10-µg/ml increase in TCZ concentration correlated with being in a state of CDAI remission or low disease activity (odds ratio [OR], 1.41) vs a moderate/high disease activity state.

Moreover, an OR of 1.52 was associated with being in a state of Health Assessment Questionnaire–Disability Index remission.

Univariate linear models showed an inverse association between BMI and improvement in the CDAI score, as well as between BMI score and lower TCZ concentrations. Of note, patients weighing >100 kg showed lower TCZ concentrations.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.